Jaime Levy

Aim. The primary aim was to evaluate the use of optical coherence tomography angiography (OCTA) versus fluorescein angiography (FA) for detecting and monitoring retinal neovascularization (NV) in patients with proliferative diabetic retinopathy (PDR) receiving treatment with anti-vascular endothelial growth factor (anti-VEGF). Methods. Treatment-naïve patients with PDR, willing to begin anti-VEGF treatment without laser from 9/2018–2/2020 were included. FA and OCTA scans were obtained at baseline, and a second OCTA scan was performed after 6 months of anti-VEGF therapy. We calculated sensitivity and specificity for two masked graders with respect to identifying NV on OCTA versus FA. Using ImageJ software, we also measured the change in NV size, at baseline and 6-month follow-up. Results. Ten eyes in eight patients were included, of which three eyes in three patients received a 6-month follow-up examination. Mean age was 51.7 ± 11.2 years, and 75% of patients were male. Overall, 21 NV sites in the 10 eyes were identified both clinically and on FA. Using OCTA scans, the sensitivity and specificity for both graders were extremely high, ranging from 95.2% to 100%. At 6-month follow-up, NV size decreased by 69.8%. Conclusion. These results suggest that OCTA may provide a suitable alternative to FA for visualizing, measuring, and monitoring changes in retinal NV in patients with PDR who receive anti-VEGF therapy.